2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Generic challenges, the next first-to-files, GDUFA dues (FY 2016) and more

PharmaCompass has assessed the second quarter US Drug Master File (DMFs) filings. In our view, with